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The etiopathogenesis of vulvar intraepithelial neoplasia (VIN III) and
invasive squamous cell carcinoma are largely unknown. Since there
are few studies on Brazilian patients, our purpose was to determine the
frequency of human papillomavirus (HPV) infection and the expres-
sion of p53 in these lesions, and associate them with other factors such
as age, morphological subtypes, multicentric and multifocal disease.
Thirty-eight cases of VIN III, nine of superficially invasive carcinoma,
and 55 of invasive vulvar carcinoma were retrospectively evaluated
from 1983 to 1995 for the presence of HPV by immunohistochemistry
and in situ hybridization, and for p53 protein expression by immuno-
histochemistry on paraffin sections. All cases for whom material
(slides and paraffin blocks) and clinical data were available were
included. HPV and p53 were detected in 57.9 and 21.1% of the VIN III
lesions, 33.3 and 66.7% of superficially invasive carcinomas, and 7.3
and 58.2% of invasive squamous cell carcinomas, respectively. HPV
infection was associated with younger age in the VIN III and invasive
carcinoma groups. In the latter, HPV infection was associated with the
basaloid variant. p53 expression rate was higher in superficially
invasive and invasive lesions and was not related to HPV infection.
Our findings are similar to others and support the hypothesis that there
are two separate entities of the disease, one associated with HPV and
the other unrelated, with p53 inactivation possibly being implicated in
some of the cases.
Correspondence
D.E.S. Engelman






Publication supported by FAPESP.
Received September 9, 2002








Several lines of evidence have shown the
involvement of human papillomavirus (HPV)
in cervical carcinogenesis (1-4). Its onco-
genic role has been attributed to a transform-
ing capacity of the oncogenic types 16/18,
encoding two transforming gene products,
the E6 and E7 oncoproteins. One of the
mechanisms described is the interaction of
E6 with the tumor suppressor gene p53 prod-
uct, leading to loss of its normal function and
thus to impaired cell proliferation and re-
parative function, increased susceptibility to
mutations, and malignant transformation
(2-7).
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A number of epidemiological studies have
linked vulvar squamous cell carcinoma to
some of the risk factors described for cervi-
cal carcinoma, and it has been shown that a
proportion of the former are associated with
HPV infection (8,9). It seems that HPV is
related to a minority of cases, especially in
younger women, with the basaloid variant of
squamous carcinoma and associated vulvar
intraepithelial neoplasia (VIN) (1,2,9,10).
HPV DNA is detected in about 10-20% of all
vulvar squamous cell carcinomas (6,11,12),
and in 50-80% of the basaloid subtype of
invasive carcinoma (2,5,8,11). However,
most vulvar carcinomas occur in older pa-
tients, are predominantly of the usual kerati-
nizing type and are associated with lichen
sclerosus and squamous hyperplasia, sug-
gesting that vulvar carcinomas may have
different etiologies, with HPV and other fac-
tors possibly playing a significant role and
are still a matter of debate (1,2,9,10-14).
Current data point to the p53 gene as the
leading factor in the surveillance of DNA
integrity. Inactivation of its tumor suppress-
ing activity seems to be an almost universal
step in the development of human malignan-
cies and may also be related to tumor pro-
gression (2,4,6,7).
p53 inactivation in vulvar carcinomas
can occur either by interaction with HPV E6
oncoprotein, or by p53 gene mutation in the
absence of the virus. In addition, several
cellular proteins and events can also interfere
with or inhibit p53-mediated transactivation
functions (2-7,13). p53 expression has been
described in 50 to 88% of cases of vulvar
squamous cell carcinoma (2,5,6,15-18).
The purpose of the current study was to
determine the frequency of HPV infection
and p53 expression in primary VIN and in-
vasive squamous cell carcinoma in Brazilian
patients and to associate them with other
factors such as age and morphologic sub-
types. Since there are few studies on vulvar
neoplasia in Brazil, our intention was to
compare our findings with those for the
worldwide population described in the lit-
erature, and to contribute additional cases.
Material and Methods
In a retrospective study conducted from
1983 to 1995, 38 cases of VIN grade III, nine
of superficially invasive carcinoma, and 55
of invasive squamous cell carcinoma of the
vulva were collected and reviewed from the
files of the Department of Pathology of the
State University of Campinas.
Biopsies were taken from areas found to
be altered upon physical examination or that
were positive for the Collins test. Our selec-
tion was based on the most representative
fragment of the lesion, the presence of histo-
logical signs consistent with HPV infection,
and the presence of altered and normal epi-
thelium adjacent to the neoplasia.
Multiple neoplastic lesions in the vulvar
region separated by non-neoplastic epithe-
lium were considered to be multifocal dis-
ease. The presence of intraepithelial neopla-
sia or invasive carcinoma at other sites of the
lower female genital tract such as the vagina
and uterine cervix was considered to be mul-
ticentric disease. Superficially invasive car-
cinoma was defined as stromal invasion of
1 mm or less (19).
Patient age, morphological type of the
neoplasia, the presence of multifocal and
multicentric lesions, and the epithelial alter-
ations adjacent to the neoplasia were ana-
lyzed and correlated with HPV detection and
p53 expression.
New sections of paraffin-embedded speci-
mens were placed on sylanized slides for
immunohistochemistry and in situ hybrid-
ization. The specimens were deparaffinized
and rehydrated.
Immunohistochemistry was performed
for HPV and p53 protein detection respec-
tively using the anti-HPV polyclonal anti-
body (Dakopatts, Carpinteria, CA, USA) di-
luted 1:150, and the monoclonal antibody
clone DO-7 (Dakopatts) diluted 1:100, which
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detects both the wild-type and mutant forms
of the p53 protein, after inhibition of endog-
enous peroxidase with 3% hydrogen peroxi-
dase in methanol solution. Antigen retrieval
was performed by heating with a household
microwave oven (2 cycles of 5 min each at
750 W for HPV detection and 3 cycles of 7
min each at 750 W for p53) in 10 mM citrate
buffer, pH 6.0. After rinsing with PBS solu-
tion, the slides were exposed to a biotinyl-
ated secondary antibody (polyclonal, 1:200;
Multilink, Dako, Carpinteria, CA, USA). The
reaction was visualized by the streptavidin-
biotin-peroxidase method (Dakopatts). The
slides were stained with diaminobenzidine
substrate solution and counterstained with
Mayer’s hematoxylin.
In situ hybridization was performed with
biotinylated probes for HPV types 6/11, 16/
18, and 31/35/51 (Dakopatts), after diges-
tion with a 0.08% (w/v) pepsin solution
(Sigma, St. Louis, MO, USA) at 37ºC for 10
min. After overnight incubation of tissue
with the probes at 37ºC and rinsing with
stringent solution (1:50, Dakopatts), the re-
action was visualized using the streptavidin-
biotin-peroxidase detection system (CSA
System, Dakopatts). The slides were stained
with diaminobenzidine substrate solution and
counterstained with Mayer’s hematoxylin.
Positive and negative controls were in-
cluded in each protocol. Immunostaining for
p53 protein was assessed by a semiquantita-
tive method, considering the number of posi-
tive cells and their intensity within the nega-
tive epithelium, and graded as follows:
- (negative), + (less than 10.0% of positive
cells), ++ (10.0% or more, and less than
50.0% of positive cells), and +++ (50.0% or
more of positive cells) (17,19,20). At least
200 cells were analyzed in each case. HPV
was considered to be absent (-) or present (+)
regardless of the number of positive nuclei
for both methods.
Statistical analysis was performed using
the Statistical Analysis System software pack-
age (SAS Institute Inc., Cary, NC, USA) and
“EpiInfo, 6.02b” (Centers for Disease Con-
trol and Prevention, Atlanta, GA, USA) and
one of the following tests when appropriate:
chi-square test to analyze the association
between the variables in the three groups of
carcinomas, Fisher exact test when the ex-
pected value was less than five, and Student
t-test when comparing ages. Univariate and
multivariate logistic regression analysis was
performed to verify which of the variables
analyzed were associated with HPV detec-
tion and p53 expression. A P value of 0.05 or
less was considered to be statistically sig-
nificant.
The present study was approved by the
Research Ethics Committee of the Faculty of




 This group included 38 patients with a
mean age (± SD) of 47.5 ± 19.9 years. Mul-
ticentric disease (macroscopic) was present
in 36.8% of the cases and multifocal lesions
(microscopic) in 34.2%. Histological sub-
types were mostly warty (92.0%) and basaloid
in only 8.0%. In 42.1% of the cases there was
an association with HPV-induced lesions
and in 6.0% with squamous hyperplasia.
HPV was detected by one of the methods in
22 of 38 cases (57.9%), and p53 expression
in 21.1%, all of them graded as (+), i.e., with
less than 10.0% of positive cells. HPV type
6/11 alone was present in one case, and
HPV 16/18 in 16 cases, three of them asso-
ciated with HPV 6/11 and one with HPV 31/
35/51. In five cases, HPV was detected only
by immunohistochemistry. The presence
of HPV infection was associated with
younger patient age (40.8 vs 57.3 years, P =
0.02). p53 expression was not related to any
of the parameters analyzed, such as age,
HPV detection and histological subtype of
VIN III.
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Invasive squamous cell carcinoma
This group included 55 patients with a
mean age of 67.8 ± 12.5 years. Multicentric
disease was present in 7.3% and multifocal
lesions in 23.6% of the cases. Histological
subtypes were: 78.2% usual keratinizing,
10.9% basaloid, 7.3% warty and 3.6% verru-
cous. Associated epithelial changes corre-
sponded mostly to dystrophic lesions (60.0%),
but VIN III (25.5%) and HPV-associated le-
sions (7.3%) were also present. The remaining
cases (7.2%) contained normal adjacent epi-
thelium. Inguinal nodal metastases were pres-
ent in 56.8% of the cases and in 16.4%, the
disease was recurrent. HPV capsid antigen
was detected in three cases and HPV DNA in
two. Overall, HPV was detected by one of the
methods in 4 of 55 cases (7.3%), all of them
HPV type 16/18. p53 was expressed in 58.2%
of the cases, being graded as ++/+++ in 47.4%.
HPV detection was associated with younger
age, presence of other neoplastic lesions in the
female lower genital tract, and presence of the
basaloid subtype of invasive carcinoma. How-
ever, by logistic regression analysis, only age
(46 vs 69.5 years, P = 0.05) and the presence of
multicentric disease (P = 0.04) remained sig-
nificant. p53 expression was only related to
depth of invasion (P = 0.04). Patients with the
basaloid subtype of invasive carcinoma were
younger (mean age, 56.8 years), and this sub-
type was associated with VIN III in 83.3% and
with dystrophic lesions in the adjacent epithe-
lium in 16.7%. HPV was present in 50.0% and
p53 in 33.3% of the cases. For the usual
keratinizing type, mean age was 68.9 years,
and this subtype was associated with VIN III in
20.9% and with dystrophic lesions in 60.5%.
HPV was detected in 2.3% and p53 in 60.5%
of these cases. In five patients (11.6%) there
was no abnormality in the adjacent epithelium
and in three (7.0%), no adjacent epithelium
was available for evaluation.
Lymph node metastasis was associated
with involvement of the clitoris (P = 0.005),
tendency to a tumor size larger than 2 cm
(P = 0.05), and grade of the neoplasia (P =
0.05).
When more than one exam for the same
patient was available in our files we com-
pared the presence of relapse in the invasive
vulvar carcinoma group. Relapse was asso-
ciated with younger mean age (54.6 ± 13.8 vs
70.3 ± 10.5 years, P = 0.0002) and was not
related to the presence of multicentric and
multifocal disease, or to HPV detection and
p53 expression.
Superficially invasive carcinoma
The mean age of the nine patients with
superficially invasive carcinoma was 57.9 ±
16.6 years. Multicentric disease was present
in five cases and multifocal lesions in five. In
eight cases, the warty type of VIN III was
present in adjacent epithelium and HPV-
associated lesions were present in two. HPV
was detected in three cases (33.3%) and p53
in six (66.7%).
Table 1 summarizes the main clinicopatho-
logical data of the three groups of lesions.
Discussion
In agreement with other reports, we show
Table 1. Clinicopathological findings of patients with three types of lesions.
Variables VIN III SIC Invasive carcinoma
(N = 38) (N = 9)  (N = 55)
Age (mean ± SD; years) 47.5 ± 19.9 57.9 ± 16.6 67.8 ± 12.5
Multicentric disease 14 (36.8) 5 (55.6) 4 (7.3)
Multifocal lesions 13 (34.2) 5 (55.6) 13 (23.6)
HPVAL 16 (42.1) 2 (22.2) 4 (7.3)
HPV capsid antigen 13 (34.2) 3 (33.3) 3 (5.5)
HPV DNA 17 (44.7) 2 (22.2) 2 (3.6)
HPV antigen or DNA 22 (57.9) 3 (33.3) 4 (7.3)
p53 expression 8 (21.1) 6 (66.7) 32 (58.2)
HPV: human papillomavirus; HPVAL: lesions with histological changes consistent
with HPV infection (HPV-associated lesions); SIC: superficially invasive carcinoma of
the vulva; VIN III: vulvar intraepithelial neoplasia grade III. The numbers within paren-
theses are percent. The invasive carcinoma group was statistically different from VIN
III and SIC groups, which were similar except for p53 expression. p53 expression was
similar for the invasive carcinoma and SIC groups and significantly different from the
VIN III group. P < 0.001, chi-square test for proportions.
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that HPV infection associated with VIN III
lesions occurred predominantly in younger
patients, and was not related to p53 expres-
sion (6,15,16,21).
In spite of having detected only nine
patients with superficially invasive vulvar
carcinomas between 1983 and 1995, our
intention was to identify any similarity with
the VIN III or with the invasive carcinoma
group. Their clinicopathological character-
istics resembled those of the VIN III group,
except for the p53 protein, with a rate similar
to that of the invasive carcinoma group. The
association with VIN III in the adjacent epi-
thelium in eight of nine superficially inva-
sive vulvar carcinomas indicates that VIN III
lesions may progress to invasive disease
(10,14,22).
HPV infection is related to VIN III le-
sions and to a small subset of younger pa-
tients with invasive vulvar carcinoma of the
basaloid variant, which is frequently associ-
ated with adjacent VIN III (1,2,9-11). Most
patients with invasive carcinomas have the
usual histological type, which is related nei-
ther to HPV infection nor to VIN III lesions,
and is associated with higher rates of dystro-
phic lesions (1,2,9-14).
The finding of high rates of p53 expres-
sion in invasive carcinoma supports the role
of p53 inactivation, either by mutation or by
binding with HPV E6 oncoprotein (2-7).
Nevertheless, as also reported elsewhere
(17,23), p53 expression was not related to
HPV infection, being negative in 20 of the
55 cases and both (p53 and HPV) positive in
only one case. This indicates that other fac-
tors besides HPV infection and p53 inactiva-
tion may be involved in the development of
vulvar carcinoma (1,2,9,11-13).
Our low rate of HPV and the finding of
the oncogenic type 16/18 in most of the
positive cases were similar to that reported
in the literature for vulvar carcinoma (9,12).
However, the rate was lower than in other
studies in which a more sensitive technique
(PCR) was used (5,8,12). Our study was
performed on formalin-fixed and paraffin-
embedded tissues. Although the more sensi-
tive methods can be performed on this kind
of specimens, DNA damage reduces their
sensitivity. In our experience (data not
shown), DNA extraction from paraffin-em-
bedded tissues is successful in only a quarter
of the cases, a fact that would reduce even
more our series. In addition, topographic
relations are lost using these methods. For
this reason, in situ hybridization was adopted
in the present study.
The condylomatous subtype of squamous
cell carcinoma presented characteristics simi-
lar to those of the usual type and was not
associated with the presence of HPV infec-
tion. This finding is in contrast to data re-
ported for other series (9). However, this
could be due to the small number of this
carcinoma variant in our study, or to limita-
tions of the method applied, i.e., in situ
hybridization.
The low rate of p53 expression in VIN III
lesions, and the higher rate in superficially
invasive and invasive carcinoma suggest that
p53 expression occurs as a late event in
vulvar carcinogenesis, and is related to the
capacity of stromal invasion by the neopla-
sia, as described for other sites (23). In our
study, among the patients with invasive car-
cinoma, p53 detection was related only to
the depth of invasion, and was not related to
the presence of lymph node metastases or
recurrent disease. These findings are similar
to some studies (2) and contrast with others
(6,8,16).
VIN III is not a frequent condition and
little is known about its natural history, but
most studies have shown a low rate of pro-
gression to invasive disease of about 10.0%
(22,24). Studies of p53 in VIN lesions are
rare, most of them associated with invasive
carcinoma, and with contradictory results.
Some have shown that p53 protein expres-
sion increased with the severity of the intra-
epithelial neoplasia, suggesting that p53 ex-
pression is related to the proliferation of
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abnormal cells (13,14). Although more re-
search is necessary, it seems that p53 might
be useful as a progression marker for intra-
epithelial neoplastic lesions (13,14).
In order to reduce surgical morbidity, to
identify which patients will develop recur-
rent disease and metastasis, several prognos-
tic markers have been proposed, including
p53 (12,25,26). There are also studies inves-
tigating its role as a predictor of radiotherapy
and chemotherapy resistance (7,25). How-
ever, the results are contradictory. Some re-
ports associate the presence of p53 mutation
or protein expression with a worse outcome,
high rates of metastasis and advanced stage
(6,16), while others do not (2,13,26), al-
though the latter studies reported that p53
was associated with the disease-free inter-
val. According to some reports, recurrent
disease is not associated with HPV or p53
protein detection (2,12,13,25,26). More re-
search is needed to determine the role of p53
in the progression of the disease, as a prog-
nostic marker and as a predictor of the tumor
response to different treatments.
The characteristics of our patients are
similar to those described in the literature
and support the hypothesis that there are two
separate entities of the disease, with HPV
infection being responsible for the develop-
ment of VIN III lesions and for a few cases of
vulvar carcinomas (1,2,9,11,12). On the other
hand, p53 alterations may be implicated in
the pathogenesis of most cases of invasive
vulvar carcinomas (5,6,13,15). However,
36.4% of the cases were negative for both
HPV and p53, indicating that about one-
third of the vulvar carcinomas might arise
through a still unknown mechanism inde-
pendent of p53 inactivation or HPV infec-
tion (12-14).
The number of cases in our study was
higher than in several published reports. Until
recently, vulvar studies were scarce and the
etiology of vulvar carcinoma and its path-
ways are still a matter of debate. In addition,
few vulvar studies are available in Brazil and
our intention was to contribute additional
cases, to compare our findings with pub-
lished reports, and to stimulate further inves-
tigations on vulvar diseases.
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